Authorized purpose: Quantitative coronary-calcium analysis and risk stratification on existing non-contrast, non-gated chest CT studies.
Clinical role
Post-processing coronary-artery segmentation, calcium scoring, and risk-stratification support
Images and patients
CT/CTA · Heart and coronary arteries, specifically the right and left coronary arteries
Key limitation
Keep in mind: Use is limited to adults older than 40, existing non-contrast/non-gated chest CT studies that include the heart, and GE or GE-subsidiary CT equipment. The FDA packet states that no clinical study was considered necessary for this version and supports equivalence with nonclinical testing; performance outside the stated acquisition/device conditions is not established.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Quantitative coronary-calcium analysis and risk stratification on existing non-contrast, non-gated chest CT studies.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and coronary arteries, specifically the right and left coronary arteries Input: Existing DICOM 3.0 non-contrast, non-gated chest CT studies that include the heart, from adult patients older than 40 and acquired on General Electric or GE-subsidiary CT equipment; other manufacturers are not validated or recommended.
Who uses it?Intended users: Healthcare professionals, including radiologists and cardiologists
What does the software produce?Output: Agatston coronary-calcium score; segmentation and evaluation of the right and left coronary arteries; percentile-based risk categories based on score, age, and gender; and an arterial-age calculation added in the submitted version 2.0 feature summary.
What is its most important limitation?Key limitation: Use is limited to adults older than 40, existing non-contrast/non-gated chest CT studies that include the heart, and GE or GE-subsidiary CT equipment. The FDA packet states that no clinical study was considered necessary for this version and supports equivalence with nonclinical testing; performance outside the stated acquisition/device conditions is not established.
Clinical takeaway. Clinical role: Quantitative coronary-calcium analysis and risk stratification on existing non-contrast, non-gated chest CT studies.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: no new clinical study was considered necessary before release, and the submission's substantial-equivalence conclusion relies on nonclinical testing. The packet discloses no new FDA clinical cohort or sensitivity, specificity, AUC, or other clinical performance metric for K243696.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Quantitative coronary-calcium analysis and risk stratification on existing non-contrast, non-gated chest CT studies.
Existing DICOM 3.0 non-contrast, non-gated chest CT studies that include the heart, from adult patients older than 40 and acquired on General Electric or GE-subsidiary CT equipment; other manufacturers are not validated or recommended.
Agatston coronary-calcium score; segmentation and evaluation of the right and left coronary arteries; percentile-based risk categories based on score, age, and gender; and an arterial-age calculation added in the submitted version 2.0 feature summary.
Use is limited to adults older than 40, existing non-contrast/non-gated chest CT studies that include the heart, and GE or GE-subsidiary CT equipment. The FDA packet states that no clinical study was considered necessary for this version and supports equivalence with nonclinical testing; performance outside the stated acquisition/device conditions is not established.
FDA packet: no new clinical study was considered necessary before release, and the submission's substantial-equivalence conclusion relies on nonclinical testing. The packet discloses no new FDA clinical cohort or sensitivity, specificity, AUC, or other clinical performance metric for K243696.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: no new clinical study was considered necessary before release, and the submission's substantial-equivalence conclusion relies on nonclinical testing. The packet discloses no new FDA clinical cohort or sensitivity, specificity, AUC, or other clinical performance metric for K243696.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Aview CAC regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K243696
IndependenceIndependence not established
K243696
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243696. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Existing DICOM 3.0 non-contrast, non-gated chest CT studies that include the heart, from adult patients older than 40 and acquired on General Electric or GE-subsidiary CT equipment; other manufacturers are not validated or recommended.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: PC-installed software using DICOM 3.0 for image storage, transfer, query, and display on-premises, with access through mobile devices and Chrome browsers; the FDA packet does not establish a specific PACS, RIS, or EHR interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Agatston coronary-calcium score; segmentation and evaluation of the right and left coronary arteries; percentile-based risk categories based on score, age, and gender; and an arterial-age calculation added in the submitted version 2.0 feature summary.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Agatston coronary-calcium score; segmentation and evaluation of the right and left coronary arteries; percentile-based risk categories based on score, age, and gender; and an arterial-age calculation added in the submitted version 2.0 feature summary.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-09-01
Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
PC-installed software using DICOM 3.0 for image storage, transfer, query, and display on-premises, with access through mobile devices and Chrome browsers; the FDA packet does not establish a specific PACS, RIS, or EHR interface.
On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K243696 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.